CAR-T cell therapy has transformed outcomes in certain blood cancers, but it has always carried the fundamental vulnerability that the cells that make it work do not always last. Infused T cells can expand, contract, and exhaust, in turn leaving patients who initially responded without the sustained immune pressure needed to prevent relapse. Understanding why some patients maintain durable remissions while others do not has pointed the field toward a rare immune cell subset that may hold the answer.
Stem cell-like memory T cells, known as Tscm cells, occupy a unique position in the T cell differentiation hierarchy. Phenotypically resembling naive T cells, they are in fact the least differentiated of the memory T cell subpopulations, sitting at the apex of the memory hierarchy as progenitors capable of giving rise to all downstream memory and effector subsets. Their defining properties, such as self-renewal, long-term persistence, and potent antitumor activity, make them a compelling foundation for cell therapies that need to outlast the tumor.
A clinical proof of concept
A recent direct demonstration of Tscm biology's therapeutic potential arrived in May 2026, when researchers co-led by Luca Gattinoni of the Leibniz Institute for Immunotherapy and James Kochenderfer of the National Cancer Institute published results from the first clinical evaluation of CAR-T cells engineered to acquire a Tscm phenotype in Cell. The study reported that CAR-Tscm cells demonstrated a favorable safety profile and induced complete remissions at remarkably low doses without the chemotherapy preconditioning typically used to enhance CAR-T engraftment.
Standard CAR-T protocols require chemotherapy to create space for infused cells and suppress immune rejection, adding toxicity, limiting the populations eligible for treatment, and complicating outpatient administration. That CAR-Tscm cells could achieve complete remissions without this step reflects the potency that comes from their self-renewal capacity and proliferative fitness: They do not need a depleted immune environment to expand effectively.
That result provides a clinical proof of concept for what preclinical models had long suggested. In mesothelioma models, CD8+ Tscm cells demonstrated superior antitumor activity compared with conventional central memory and effector memory T cells. In solid tumor models more broadly, less differentiated T cell subpopulations — including Tscm cells — have been consistently associated with better clinical outcomes, longer persistence, and greater antitumor efficacy than more terminally differentiated products.
The solid tumor challenge
If Tscm biology solves persistence in hematologic malignancies, the harder question is whether it can do the same in solid tumors — where the immunosuppressive tumor microenvironment (TME) actively works against T cell function. The Tscm subpopulation typically represents only a small fraction of CAR-T cells in solid tumor settings, suppressed by the TME before the cells can establish durable antitumor responses.
Several engineering strategies are being pursued to address this. Cytokine armoring — equipping CAR-T cells to produce or respond to interleukin-15 (IL-15) — has emerged as one of the most studied approaches. IL-15 inhibits activation-induced CAR-T cell death, restores effector function, and promotes a Tscm-like phenotype with enhanced memory characteristics, improving effectiveness against solid tumors in preclinical settings. Co-expression of membrane-bound chimeric IL-15 with the CAR construct has been shown to drive long-term T cell persistence exhibiting a memory stem-cell phenotype in preclinical models.
Logic gating represents another engineering direction relevant to solid tumor applications — ensuring that CAR-T cells are activated only when multiple tumor-associated antigens are simultaneously present, reducing on-target, off-tumor toxicity while preserving the potency needed to eliminate disease. For targets like claudin 18.2, where single-antigen targeting carries gastrointestinal toxicity risk, AND-gate designs that require co-expression of a second antigen allow higher-dose treatment with improved safety profiles.
The manufacturing piece is equally important. Preserving Tscm-enriched starting populations and preventing exhaustion during the ex vivo expansion process that CAR-T manufacturing requires has proved technically demanding. Shorter manufacturing timelines, optimized culture conditions, and selection strategies that favor less-differentiated T cell inputs are areas of active development, with the goal of delivering a product whose phenotypic composition reflects the biology that drives durable responses — not just the biology that survives the manufacturing process.
What clinical programs are showing
Several programs in clinical development are now explicitly engineering for Tscm enrichment or using manufacturing approaches designed to preserve stemness. In multiple myeloma, investigators have reported deep and durable responses in heavily pre-treated patients, outcomes that depend substantially on the persistence and self-renewal capacity of the infused cells rather than initial expansion alone.
In hepatocellular carcinoma (HCC), where GPC3-targeted CAR-T approaches are under investigation, investigators have described disease control rates of 90 percent and objective response rates of 60 percent in heavily pre-treated patients and are moving toward combination strategies with local therapies such as ablation and radiotherapy that are designed to leverage the immune memory capacity of the infused cells to prevent recurrence following initial tumor reduction.
The question of whether Tscm-enriched products will translate the persistence advantages seen in liquid tumors into durable responses in solid tumor settings remains open. What is becoming clear is that product composition is a meaningful determinant of outcomes that the field is increasingly learning to measure, engineer, and optimize.
Toward mainstream cell therapy
The trajectory of Tscm-focused cell therapy development points toward a goal that the field has articulated but not yet achieved at scale: Cell therapies that function more like living medicines than like conventional biologics that are dosed and cleared.
A 2026 review of CAR-T cell therapies for solid tumors noted that less-differentiated central memory and stem cell-memory T cells have been associated with superior expansion and long-term remission, and identified Tscm enrichment as one of the key biological parameters distinguishing next-generation products from first-generation approaches. The same review highlighted inosine supplementation, hypoxic manufacturing conditions, and specific costimulatory domain choices as among the strategies being actively evaluated to preserve stemness through the manufacturing process and into the clinic.
Clinical proof of concept established a combination of safety and efficacy that, if reproducible across indications, would meaningfully change what cell therapy can be offered to and tolerated by. Whether that result extends to solid tumors — which present the more formidable biological challenge — is the question that the next generation of Tscm-focused programs will have to answer.
